Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bexagliflozin DDI Study with Probenecid, Rifampin, and Verapamil
NCT03296800Phase 1Completed
- Sponsor
- Theracos, Inc.
- Start
- Sep 2017
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of bexagliflozin in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Theracos, Inc. Primary endpoints: Maximum Observed Plasma Concentration up to 48 hours, Time of Maximum Observed Plasma Concentration up to 48 hours and 2 more. Started Sep 2017; status: completed.
02
Drugs
bexagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03296800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03296800.